Three-dimensional (3D) magnetic resonance volume assessment and loco-regional failure in anal cancer: early evaluation case-control study.
Anal cancer
Loco-regional failure
Prognosis
Tumour volume
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
30 Nov 2020
30 Nov 2020
Historique:
received:
15
07
2020
accepted:
03
11
2020
entrez:
1
12
2020
pubmed:
2
12
2020
medline:
13
5
2021
Statut:
epublish
Résumé
The primary aim was to test the hypothesis that deriving pre-treatment 3D magnetic resonance tumour volume (mrTV) quantification improves performance characteristics for the prediction of loco-regional failure compared with standard maximal tumour diameter (1D) assessment in patients with squamous cell carcinoma of the anus undergoing chemoradiotherapy. We performed an early evaluation case-control study at two UK centres (2007-2014) in 39 patients with loco-regional failure (cases), and 41 patients disease-free at 3 years (controls). mrTV was determined using the summation of areas method (Vol The median time per patient for Vol Preliminary results suggest that the replacement of mrTV for mrT-size improves prediction of loco-regional failure after chemoradiotherapy for squamous cell carcinoma of the anus. However, mrTV calculation is time consuming and variation in its reproducibility are drawbacks with the current technology.
Sections du résumé
BACKGROUND
BACKGROUND
The primary aim was to test the hypothesis that deriving pre-treatment 3D magnetic resonance tumour volume (mrTV) quantification improves performance characteristics for the prediction of loco-regional failure compared with standard maximal tumour diameter (1D) assessment in patients with squamous cell carcinoma of the anus undergoing chemoradiotherapy.
METHODS
METHODS
We performed an early evaluation case-control study at two UK centres (2007-2014) in 39 patients with loco-regional failure (cases), and 41 patients disease-free at 3 years (controls). mrTV was determined using the summation of areas method (Vol
RESULTS
RESULTS
The median time per patient for Vol
CONCLUSION
CONCLUSIONS
Preliminary results suggest that the replacement of mrTV for mrT-size improves prediction of loco-regional failure after chemoradiotherapy for squamous cell carcinoma of the anus. However, mrTV calculation is time consuming and variation in its reproducibility are drawbacks with the current technology.
Identifiants
pubmed: 33256671
doi: 10.1186/s12885-020-07613-7
pii: 10.1186/s12885-020-07613-7
pmc: PMC7706015
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1165Références
Clin Chem. 2008 Apr;54(4):729-37
pubmed: 18258670
Nat Rev Clin Oncol. 2017 Mar;14(3):169-186
pubmed: 27725679
Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):553-7
pubmed: 9486604
Clin Transl Radiat Oncol. 2018 Jun 11;11:33-39
pubmed: 29928706
J Nucl Med. 2013 Jan;54(1):27-32
pubmed: 23236018
Eur Radiol. 2017 Feb;27(2):607-617
pubmed: 27090113
Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):490-5
pubmed: 20472349
Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13
pubmed: 16028002
Radiat Oncol. 2010 Feb 06;5:10
pubmed: 20137093
Radiat Oncol. 2013 Sep 05;8:208
pubmed: 24007375
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):382-9
pubmed: 11872283
Radiother Oncol. 1997 Jul;44(1):23-9
pubmed: 9288853
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Radiother Oncol. 2019 May;134:119-126
pubmed: 31005205
Head Neck. 2007 Feb;29(2):104-8
pubmed: 17111434
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5
pubmed: 16626889
Dis Colon Rectum. 2008 Feb;51(2):147-53
pubmed: 18180997
Eur J Radiol. 2016 Aug;85(8):1390-4
pubmed: 27423677
Lancet Oncol. 2013 May;14(6):516-24
pubmed: 23578724
Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):638-45
pubmed: 24035327
Clin Oncol (R Coll Radiol). 2012 Feb;24(1):52-63
pubmed: 22035634
Int J Radiat Oncol Biol Phys. 1993 Sep 1;27(1):67-73
pubmed: 7690019
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):21-7
pubmed: 15093895
Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):835-46
pubmed: 12095548
Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12
pubmed: 17569110
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1560-71
pubmed: 16863933
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):552-8
pubmed: 22019078
Cancer. 2013 Feb 15;119(4):748-55
pubmed: 23011911
Eur Radiol. 2018 Apr;28(4):1512-1519
pubmed: 29134349
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):449-54
pubmed: 16226400
Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1366-72
pubmed: 11483349
Radiother Oncol. 2014 Jun;111(3):330-9
pubmed: 24947004
Jpn J Clin Oncol. 2011 Apr;41(4):537-42
pubmed: 21242183
J Clin Oncol. 1997 May;15(5):2040-9
pubmed: 9164216
Onkologie. 2008 May;31(5):251-7
pubmed: 18497514
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800
pubmed: 17379452
Br J Cancer. 2020 Mar;122(6):749-758
pubmed: 31932755
Hematol Oncol Clin North Am. 2012 Dec;26(6):1315-50
pubmed: 23116582
Radiother Oncol. 2009 Jun;91(3):455-60
pubmed: 19339069
J Clin Oncol. 2012 Dec 10;30(35):4344-51
pubmed: 23150707
Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):277-88
pubmed: 9788405
Br J Cancer. 2017 Jan 17;116(2):156-162
pubmed: 27923035
Br J Surg. 2005 May;92(5):605-14
pubmed: 15739215